Gunnar Juliusson
11 – 20 of 149
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years
(
- Contribution to journal › Article
-
Mark
Impact of treatment delay in acute myeloid leukemia revisited
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : The HOVON-SAKK-132 trial
(
- Contribution to journal › Article
-
Mark
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
(
- Contribution to journal › Scientific review
-
Mark
Epidemiology and Etiology of AML
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients
(
- Contribution to journal › Article
- 2020
-
Mark
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014 : improving performance status is a major contributing factor
(
- Contribution to journal › Letter
-
Mark
Hypo, Hyper, or Combo : New paradigm for treatment of acute myeloid leukemia in older people
(
- Contribution to journal › Scientific review
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article